Glanbia Plc · EURONEXT:GL9
Glanbia — Q1 2024 Earnings Presentation
8 slides from Glanbia's earnings presentation, May 1, 2024
Slide 1: Q1 2024 Interim Management Statement
Q1 2024 Interim Management Statement 1 May 2024 Hugh McGuire Mark Garvey Chief Executive Officer Chief Financial Officer
Slide 2: Important Notice
Important Notice This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both economic and busi
Slide 3: Q1 2024 - Highlights
Q1 2024 - Highlights • Q1 Group performance in line with expectations • Optimum Nutrition & Healthy Lifestyle performance continued with strong volume growth in the quarter • Volume trends in NS continue to improve with strong growth in the premix solutions business in the quarter • Continue to prog
Slide 4: GPN – Q1 performance
GPN – Q1 performance Revenue growth -1.9% Volume +1.4% Performance Healthy Weight Nutrition Lifestyle Management Price -3.3% • LFL* revenue -5.1% in Americas and +4.7% in International • Volume momentum continued with strong volume growth in % of GPN the protein growth brands of Optimum Nutrition, I
Slide 5: NS – Q1 performance
NS – Q1 performance Revenue growth* -2.3% Volume +3.8% Price -5.5% Acquisitions / Disposals -0.6% • Volume trends continue to improve with strong growth in the premix solutions business • Consumer demand for protein solutions remains strong, with volumes in the quarter impacted by the timing of cust
Slide 6: Flavor Producers Acquisition
Flavor Producers Acquisition Strong fit – in line with our M&A strategy to scale our flavours platform Business highlights Strategic rationale Flavours platform • Leading US independent • Unique and complimentary • Opportunity to scale NS flavours business capabilities focusing on organic flavours b
Slide 7: Financing Reiterating 2024 Guidance
Financing Reiterating 2024 Guidance Adjusted EPS growth* 5% - 8% Net debt $289m Total committed facilities of $1.3bn Revenue GPN revenue growth*: 4% - 7% growth NS volume growth: 3% - 5% FY24 capex expected to be $75 - $85m Earnings GPN & NS EBITDA margins: growth at least at 2023 margins** FY24 sha
Slide 8: Q&A
Q&A A performance driven purpose led global nutrition company 8 || Glanbia plc Q1 2024 IMS Presentation